Lilly To Offer Direct-To-Employer Programs
Eli Lilly and Co. is preparing a new direct-to-employer model that will allow companies to offer coverage for its obesity medications, including Zepbound, beginning in early 2026.
Read MoreTag Archives: Novo Nordisk
Eli Lilly Becomes First Pharmaceutical To Hit $1 Trillion Valuation
Eli Lilly and Co. on Friday, Nov. 21 became the first health care company to surpass a $1 trillion market valuation, driven by intense investor demand for its fast-growing weight-loss drug portfolio.
Read MoreTrump Announces Weight-Loss Drug Price Negotiations, Lilly Stocks Fall
Shares of Eli Lilly and Novo Nordisk fell Friday, Oct. 17 after Pres. Donald Trump said the price of the weight-loss drug Ozempic could soon drop to $150 a month.
Read MoreLilly Shares Slide Following Weight Loss Pill Trial Results
Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company’s second-quarter earnings report, alongside results from a closely watched trial of its experimental weight-loss pill.
Read More
Lilly Shares Drop After Roche Announces Result Of Obesity Drug
Shares of Eli Lilly and Co. took a two-day slide after competitor Roche announced positive results in an early-stage study on its obesity drug.
Read More